Cheson on Oncology

 
 

  • What's Hot in Hematologic Malignancies   Dr Bruce Cheson gives a sneak preview of the presentations in hematologic malignancies at ASCO 2016, with a look at new agents, refined combinations, and strategies to reduce toxicities.
  • Idelalisib Speed Bump: Shifting Gears in CLL   Dr Bruce Cheson discusses how the halt of six idelalisib trials because of adverse events, including deaths, affects research and patient management in CLL and follicular lymphoma.
  • Dark Side of the Moon: Destination for Cancer Moon Shot?   Dr Bruce Cheson gives his candid opinion, accompanied by Pink Floyd, on the likelihood of President Obama's moon shot curing cancer -- with Congress and cancer standing in the way.
  • New Hodgkin's Protocol: Brentuximab Vedotin and Nivolumab   The new treatment protocol may advance the goal of phasing out the use of nonspecific, cytotoxic chemotherapy as a treatment for this disease.
  • In Lymphoma, Chemo Challenged by New Classes, New Combinations   Drs Cheson and Flinn discuss lymphoma clinical trial data presented at the ASH 2015 meeting.
  • Toward a Chemotherapy-Free Future for CLL   Drs Bruce Cheson and Kanti Rai discuss some of the highlights in chronic lymphocytic leukemia clinical research from the 2015 American Society of Hematology meeting.
  • ASH 2015: For Lymphoma, CLL, the Action Is in Combinations   Dr Bruce Cheson previews data to be presented at the upcoming ASH 2015 meeting, the most exciting of which are from studies using combination drugs.
  • What to Expect in Hematologic Malignancies   Dr Bruce Cheson previews the most important trials being presented at ASCO 2015 on Hodgkin's and non-Hodgkin's lymphoma, acute and chronic leukemia, and multiple myeloma.
  • March Madness: Submitting Abstracts to Multiple Meetings   Dr Bruce Cheson discusses the pros and cons of investigators submitting the same data to multiple meetings.
  • The Future of Hodgkin Lymphoma -- Brentuximab and Beyond   Dr Bruce Cheson and Dr Ann LaCasce highlight data from ASH 2014 on brentuximab vedotin and discuss promising agents for Hodgkin lymphoma, including checkpoint inhibitors nivolumab and pembrolizumab.
  • CLL: It's the Best -- and Most Confusing -- of Times   Dr Bruce Cheson and Dr Susan O'Brien discuss data presented at the 2014 ASH meeting on chronic lymphocytic leukemia, with a focus on the CLL10 trial as well as ibrutinib, idelalisib, and ADT-199.
  • Double-Hit Lymphomas Explained, With Surprising EPOCH-R Data   Dr Bruce Cheson and Dr Andrew Zelenetz define 'double-hit' lymphomas and discuss trial results for these hard-to-treat patients, as well as other promising agents in lymphoma.
  • R-squared Update: Underwhelms in FL, but Impressive in MCL   Dr Bruce Cheson and Dr Nathan Fowler discuss lenalidomide clinical trial results at the 2014 ASH meeting, focusing on a trial presented by the Nordic Lymphoma Group.
  • ASH 2014: If You're Going to San Francisco…   Dr Bruce Cheson previews important data being presented at the upcoming ASH 2014 meeting, including studies of CLL, Hodgkin lymphoma, and the role of interim PET scans in large cell lymphoma.
  • What's New: Imaging in Lymphoma   Dr Bruce Cheson breaks down new consensus recommendations on the role of imaging in staging and response assessment for lymphoma.
  • CLL's 'Very Unusual Year'   Dr. Bruce Cheson discusses how to choose among the new, exciting options available for the treatment of chronic lymphocytic leukemia: obinutuzumab, ibrutinib, and idelalisib.
  • Ibrutinib Results RESONATE in Refractory CLL   Drs. Bruce Cheson and Myron Czuczman discuss lymphoma and leukemia highlights from ASCO 2014, including the RESONATE and SEXIE trials and emerging antibody-drug conjugates.
  • What to Watch in Lymphoma, Leukemia   Dr. Bruce Cheson reviews a wealth of practice-changing and practice-confirming studies from the lymphoma and leukemia sessions at ASCO 2014.
  • Save Cancer Trials From the NCI Slasher   NCI budget cuts to 2 clinical trial programs endanger patients and cripple research, says Dr. Bruce Cheson, who calls for the feds to loosen their stranglehold on clinical trials.
  • Oncologists: Burned Out -- or Burned?   Dr. Bruce Cheson reports on burnout among oncologists and surmises that compensation based solely on patient volume could prove deleterious to physician health -- and the health of the specialty.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.